Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Change in Cash (2018 - 2025)

X4 Pharmaceuticals' Change in Cash history spans 8 years, with the latest figure at $147.4 million for Q4 2025.

  • For Q4 2025, Change in Cash rose 453.31% year-over-year to $147.4 million; the TTM value through Dec 2025 reached $161.4 million, up 468.67%, while the annual FY2025 figure was $161.4 million, 468.67% up from the prior year.
  • Change in Cash reached $147.4 million in Q4 2025 per XFOR's latest filing, up from $30.4 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $147.4 million in Q4 2025 to a low of -$49.8 million in Q3 2024.
  • Average Change in Cash over 5 years is $6.9 million, with a median of -$10.1 million recorded in 2022.
  • Peak YoY movement for Change in Cash: surged 677.28% in 2022, then plummeted 926.3% in 2024.
  • A 5-year view of Change in Cash shows it stood at $5.4 million in 2021, then soared by 677.28% to $41.9 million in 2022, then plummeted by 177.26% to -$32.4 million in 2023, then fell by 28.96% to -$41.7 million in 2024, then soared by 453.31% to $147.4 million in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Change in Cash are $147.4 million (Q4 2025), $30.4 million (Q3 2025), and -$1.0 million (Q2 2025).